CN112294755A - 含有水难溶性药物的医药组合物 - Google Patents
含有水难溶性药物的医药组合物 Download PDFInfo
- Publication number
- CN112294755A CN112294755A CN202011296839.6A CN202011296839A CN112294755A CN 112294755 A CN112294755 A CN 112294755A CN 202011296839 A CN202011296839 A CN 202011296839A CN 112294755 A CN112294755 A CN 112294755A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- composition containing
- water
- polystyrene sulfonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了含有水难溶性药物的医药组合物,其特征在于,包括以下重量份数配比的原料:司维拉米盐酸盐1‑3份、聚苯乙烯磺酸盐2‑6份、甲基纤维素0.1‑0.5份、卡拉胶0.2‑0.3份、琼脂0.1‑0.2份、柠檬酸钙0.2‑0.4份、苹果酸0.1‑0.3份、麦芽糖醇液0.5‑0.7份、草莓味香料0.2‑0.3份、苯甲酸钠0.2‑0.3份。该含有水难溶性药物的医药组合物,能够减轻在服用将通常的1次服用量分包得到的分包品时的繁琐,适用于后述的管状、条状等包装,所以携带性也很优异,服药依从性提高,另外,与份量杯等体积大的包装相比,携带性非常优异,能够在维持粗糙感少与柔软的口感的同时,提高混悬与分散稳定性。
Description
技术领域
本发明涉及医药技术领域,具体为含有水难溶性药物的医药组合物。
背景技术
目前,离子交换树脂作为各种疾病的预防、治疗药品而使用。例如,阳离子交换树脂(聚苯乙烯磺酸钙、聚苯乙烯磺酸钠等)被应用于高钾血症,阴离子交换树脂(考来烯胺等)被应用于高胆固醇血症或高磷血症。
但是,以聚苯乙烯磺酸钙、聚苯乙烯磺酸钠为代表的离子交换树脂通常不溶于水,因此具有特有的舌触感(粗糙感)。
上述的散剂、干糖浆剂在服用时均需要混悬于水中,因此必须准备水和容器,比较繁琐。
另一方面,内服用凝胶剂被容纳在份量杯中,因此服用时需要勺子等,另外,份量杯本身体积大,在携带多个时比较重,因此携带性差。
发明内容
(一)解决的技术问题
针对现有技术的不足,本发明提供了含有水难溶性药物的医药组合物,具备带来的粗糙感少,不仅口感柔软,而且具有优异的混悬与分散稳定性。优点,解决了上述背景技术的问题。
(二)技术方案
为实现上述目的,本发明提供如下技术方案:含有水难溶性药物的医药组合物,包括以下重量份数配比的原料:司维拉米盐酸盐1-3份、聚苯乙烯磺酸盐2-6份、甲基纤维素0.1-0.5份、卡拉胶0.2-0.3份、琼脂0.1-0.2份、柠檬酸钙0.2-0.4份、苹果酸0.1-0.3份、麦芽糖醇液0.5-0.7份、草莓味香料0.2-0.3份、苯甲酸钠0.2-0.3份。
优选的,所述聚苯乙烯磺酸盐的粒度为5~100μm。
优选的,所述卡拉胶以外还可添加刺槐豆胶,能够提高医药组合物的弹性,所述琼脂能够提高医药组合物的硬度。
优选的,包括以下重量份数配比的原料:司维拉米盐酸盐1份、聚苯乙烯磺酸盐3份、甲基纤维素0.2份、卡拉胶0.23份、琼脂0.15份、柠檬酸钙0.24份、苹果酸0.15份、麦芽糖醇液0.51份、草莓味香料0.26份、苯甲酸钠0.23份。
优选的,包括以下重量份数配比的原料:司维拉米盐酸盐3份、聚苯乙烯磺酸盐5份、甲基纤维素0.42份、卡拉胶0.28份、琼脂0.16份、柠檬酸钙0.35份、苹果酸0.26份、麦芽糖醇液0.67份、草莓味香料0.26份、苯甲酸钠0.27份。
本发明要解决的另一技术问题是提供含有水难溶性药物的医药组合物,包括以下步骤:
1)司维拉米盐酸盐和聚苯乙烯磺酸盐进行研磨,然后搅拌混合均匀;
2)将司维拉米盐酸盐和聚苯乙烯磺酸盐加入与水互溶的有机溶剂中,搅拌混合均匀;
3)在搅拌条件下将有机溶剂与水或缓冲溶液混合,有机溶剂与水或缓冲溶液的体积比大于或等于1:3,优选为2/3~10/1,搅拌后将溶液通过微孔滤膜过滤得滤液;
4)把得到的滤液加入柠檬酸钙和苹果酸进行PH调节至5,然后再加入卡拉胶、琼脂、麦芽糖醇液和草莓味香料;
5)然后进行缓慢搅拌浓缩,在浓缩过程中加入甲基纤维素;
6)使用铝-聚乙烯制层压膜将得到的凝胶状医药组合物每50g包装成条状。
(三)有益效果
与现有技术相比,本发明提供了含有水难溶性药物的医药组合物,具备以下有益效果:
该含有水难溶性药物的医药组合物,能够减轻在服用将通常的1次服用量分包得到的分包品时的繁琐,适用于后述的管状、条状等包装,所以携带性也很优异,服药依从性提高,另外,与份量杯等体积大的包装相比,携带性非常优异,能够在维持粗糙感少与柔软的口感的同时,提高混悬与分散稳定性。
具体实施方式
下面将结合本发明的实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例一:含有水难溶性药物的医药组合物,包括以下步骤:
1)司维拉米盐酸盐1份和聚苯乙烯磺酸盐3份进行研磨,然后搅拌混合均匀;
2)将司维拉米盐酸盐1份和聚苯乙烯磺酸盐3份加入与水互溶的有机溶剂中,搅拌混合均匀;
3)在搅拌条件下将有机溶剂与水或缓冲溶液混合,有机溶剂与水或缓冲溶液的体积比大于或等于1:3,优选为2/3~10/1,搅拌后将溶液通过微孔滤膜过滤得滤液;
4)把得到的滤液加入柠檬酸钙0.24份和苹果酸0.15份进行PH调节至5,然后再加入卡拉胶0.23份、琼脂0.15份、麦芽糖醇液0.51份和草莓味香料0.26份;
5)然后进行缓慢搅拌浓缩,在浓缩过程中加入甲基纤维素0.2份;
6)使用铝-聚乙烯制层压膜将得到的凝胶状医药组合物每50g包装成条状。
实施例二:含有水难溶性药物的医药组合物,包括以下步骤:
1)司维拉米盐酸盐3份和聚苯乙烯磺酸盐5份进行研磨,然后搅拌混合均匀;
2)将司维拉米盐酸盐3份和聚苯乙烯磺酸盐5份加入与水互溶的有机溶剂中,搅拌混合均匀;
3)在搅拌条件下将有机溶剂与水或缓冲溶液混合,有机溶剂与水或缓冲溶液的体积比大于或等于1:3,优选为2/3~10/1,搅拌后将溶液通过微孔滤膜过滤得滤液;
4)把得到的滤液加入柠檬酸钙0.35份和苹果酸0.26份进行PH调节至5,然后再加入卡拉胶0.28份、琼脂0.16份、麦芽糖醇液0.67份和草莓味香料0.26份;
5)然后进行缓慢搅拌浓缩,在浓缩过程中加入甲基纤维素0.42份;
6)使用铝-聚乙烯制层压膜将得到的凝胶状医药组合物每50g包装成条状。
本发明的有益效果是:该含有水难溶性药物的医药组合物,能够减轻在服用将通常的1次服用量分包得到的分包品时的繁琐,适用于后述的管状、条状等包装,所以携带性也很优异,服药依从性提高,另外,与份量杯等体积大的包装相比,携带性非常优异,能够在维持粗糙感少与柔软的口感的同时,提高混悬与分散稳定性。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (6)
1.含有水难溶性药物的医药组合物,其特征在于,包括以下重量份数配比的原料:司维拉米盐酸盐1-3份、聚苯乙烯磺酸盐2-6份、甲基纤维素0.1-0.5份、卡拉胶0.2-0.3份、琼脂0.1-0.2份、柠檬酸钙0.2-0.4份、苹果酸0.1-0.3份、麦芽糖醇液0.5-0.7份、草莓味香料0.2-0.3份、苯甲酸钠0.2-0.3份。
2.根据权利要求1所述的含有水难溶性药物的医药组合物,其特征在于,所述聚苯乙烯磺酸盐的粒度为5~100μm。
3.根据权利要求1所述的含有水难溶性药物的医药组合物,其特征在于,所述卡拉胶以外还可添加刺槐豆胶,能够提高医药组合物的弹性,所述琼脂能够提高医药组合物的硬度。
4.根据权利要求1所述的含有水难溶性药物的医药组合物,其特征在于,包括以下重量份数配比的原料:司维拉米盐酸盐1份、聚苯乙烯磺酸盐3份、甲基纤维素0.2份、卡拉胶0.23份、琼脂0.15份、柠檬酸钙0.24份、苹果酸0.15份、麦芽糖醇液0.51份、草莓味香料0.26份、苯甲酸钠0.23份。
5.根据权利要求1所述的含有水难溶性药物的医药组合物,其特征在于,包括以下重量份数配比的原料:司维拉米盐酸盐3份、聚苯乙烯磺酸盐5份、甲基纤维素0.42份、卡拉胶0.28份、琼脂0.16份、柠檬酸钙0.35份、苹果酸0.26份、麦芽糖醇液0.67份、草莓味香料0.26份、苯甲酸钠0.27份。
6.含有水难溶性药物的医药组合物,其特征在于,包括以下步骤:
1)司维拉米盐酸盐和聚苯乙烯磺酸盐进行研磨,然后搅拌混合均匀;
2)将司维拉米盐酸盐和聚苯乙烯磺酸盐加入与水互溶的有机溶剂中,搅拌混合均匀;
3)在搅拌条件下将有机溶剂与水或缓冲溶液混合,有机溶剂与水或缓冲溶液的体积比大于或等于1:3,优选为2/3~10/1,搅拌后将溶液通过微孔滤膜过滤得滤液;
4)把得到的滤液加入柠檬酸钙和苹果酸进行PH调节至5,然后再加入卡拉胶、琼脂、麦芽糖醇液和草莓味香料;
5)然后进行缓慢搅拌浓缩,在浓缩过程中加入甲基纤维素;
6)使用铝-聚乙烯制层压膜将得到的凝胶状医药组合物每50g包装成条状。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011296839.6A CN112294755A (zh) | 2020-11-18 | 2020-11-18 | 含有水难溶性药物的医药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011296839.6A CN112294755A (zh) | 2020-11-18 | 2020-11-18 | 含有水难溶性药物的医药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112294755A true CN112294755A (zh) | 2021-02-02 |
Family
ID=74334825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011296839.6A Pending CN112294755A (zh) | 2020-11-18 | 2020-11-18 | 含有水难溶性药物的医药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112294755A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103338789A (zh) * | 2011-01-27 | 2013-10-02 | 兴和株式会社 | 含有水难溶性药物的医药组合物 |
-
2020
- 2020-11-18 CN CN202011296839.6A patent/CN112294755A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103338789A (zh) * | 2011-01-27 | 2013-10-02 | 兴和株式会社 | 含有水难溶性药物的医药组合物 |
CN108524445A (zh) * | 2011-01-27 | 2018-09-14 | 兴和株式会社 | 含有水难溶性药物的医药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4510128A (en) | Resinate of a substituted carboxylic acid, the preparation and use thereof, and pharmaceutical compositions containing it | |
US7094429B2 (en) | Process for preparing tannate liquid and semi-solid dosage forms | |
US5188825A (en) | Freeze-dried dosage forms and methods for preparing the same | |
US6022533A (en) | Tablets containing anion exchange resin | |
EP0524579B1 (en) | Improved oral dosing formulations of dideoxy purine nucleosides | |
BRPI0209134B1 (pt) | uso de um sevelamer ou um sal do mesmo e uso de um colesevelam ou um sal do mesmo | |
WO1992004013A1 (en) | Multiparticulate sustained release matrix system | |
CN104434866A (zh) | 一种碳酸司维拉姆泡腾片及其制备方法 | |
CN103784396B (zh) | 布洛芬口服微丸干凝胶及其制备方法 | |
CN108030770A (zh) | 含有药物树脂复合物的释药可控的干混悬剂及其制备方法 | |
CA1041904A (en) | Iron-resin adsorbate | |
US3665073A (en) | Pharmaceuticals prepared from polycyclic bases and cation exchange resins | |
CN112294755A (zh) | 含有水难溶性药物的医药组合物 | |
EP0873129B1 (en) | Anion exchange resin-containing tablets | |
IL99031A (en) | Solid oral pharmaceutical preparations containing epiphamide | |
EP0159735A1 (en) | Pharmaceutical composition containing tetracyclin or doxycyclin salts and a process of preparing such a composition | |
US3035979A (en) | Pharmaceutical composition containing a resin-narcotic compound and a resinantihistamine compound | |
US20130034607A1 (en) | Tablet | |
CN107375218A (zh) | 一种碳酸司维拉姆口服缓释干混悬剂 | |
EP1075257A1 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
CA1269043A (en) | Floating sustained release therapeutic compositions | |
AU723340C (en) | Anion exchange resin-containing tablets | |
EP0332600A1 (en) | Pharmaceutical compositions containing cholestyramine | |
CN116098867A (zh) | 一种阿比特龙聚合胶束制剂及其制备方法 | |
CN110037987A (zh) | 一种枸橼酸他莫昔芬脂质体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210202 |